Coulter 1997 Annual Report

Coulter 1997 Annual Report

Cahan & Associates, San Francisco, California, 1998

Description

Coulter Pharmaceutical is developing Bexxar, a new drug therapy to treat non-Hodgkin’s lymphoma, the second most fatal cancer. Most people afflicted with this disease have a maximum of seven years to live. In clinical trials, 71 percent of patients using Bexxar have had their cancer go into complete remission. Dramatic black-and-white portraits and personal testimonials convey the drama of anguish, recovery, and transformation many of these patients have experienced. The small quote next to the date on the cover reads, “I was supposed to die today.” After turning the cover, the reader sees a paragraph explaining the powerful benefits of Bexxar and how it saved this patient’s life.

Collections: Communication Graphics: 20 (1999)
Discipline: Corporate communications design
Format: Booklet

Credits

Design firm
Cahan & Associates
Creative director
Bill Cahan
Designer
Kevin Roberson
Photographer
Robert Schlatter
Writers
Kevin Roberson, Sylvia Wheeler
Typeface
Bembo
Printer
Lithographix
Paper
Potlatch McCoy Velvet
Client
Coulter Pharmaceutical
Loading...
Loading...